Biovie Inc (BIVI) Stock Price, Quote & News

Company Profile

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical t...

Industry: Biotechnology

Sector: Healthcare

Phone: 775 888 3162

Website: bioviepharma.com

Address:

680 W. Nye Lane, Suite 2014, Carson City, United States

ValuePrince Sep. 13 at 6:52 AM

$BIVI 🐩

0 · Reply

et1000 Sep. 11 at 11:06 PM

Ticker MLEC is the next nano float runner ! Every small float ticker has been running almost 500% recently Would not be surprised if they send MLEC up next. MLEC starting to make its move now! Only 573k shares outstanding! 💎 $USAR $BLMZ $BIVI $BTCT.X crypto

0 · Reply

mshah1615 Sep. 11 at 10:27 AM

$BIVI RedChip Investor Webinar with BioVie (NASDAQ: BIVI) Date & Time Sep 23, 2026 11:00 AM Eastern Time (US and Canada)

0 · Reply

TJ12000 Sep. 9 at 7:18 PM

$BIVI scam company run by greaseball who goes by donkey Kong

1 · Reply

emilyparkerr Sep. 9 at 9:18 AM

$BIVI ADDRESS-LC update: ~200 Long COVID patients enrolled. Bezisterim targets NFκB/ERK neuroinflammation — same mechanism that showed proteome-wide anti-inflammatory effect in SUNRISE-PD (283/380 proteins, p=3.2×10⁻²²). LC topline data expected 2nd–3rd week Sep. No FDA-approved LC treatment exists. https://bioviepharma.com/long-covid/

0 · Reply

TJ12000 Sep. 8 at 4:06 PM

$BIVI gypsy scam company

0 · Reply

GoldenrodGenius Sep. 8 at 2:30 PM

$BIVI sleeper stock, buy and hold.. still under the radar.

0 · Reply

LibertarianTreehugger Sep. 8 at 2:21 PM

BioVie advances Parkinson’s Phase 3 development program with FDA engagement: https://finance.yahoo.com/healthcare/articles/biovie-advances-parkinson-phase-3-135200836.html $BIVI

0 · Reply

Mistery88 Sep. 8 at 11:51 AM

$BIVI big buy

0 · Reply

mshah1615 Sep. 8 at 12:27 AM

$BIVI I still Believe that IF YOU ARE BULLISH BIVIW IS BEST BUY FOR ROI

1 · Reply

BioVie Announces Update to Parkinson's Phase 3 Development Program

2026-08-31T12:10:36.000Z - 13 days ago

BioVie completes treatment phase of ADDRESS-LC trial

Aug 31, 2026, 8:00 AM EDT - 13 days ago

BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

Aug 14, 2026, 8:00 AM EDT - 4 weeks ago

BioVie Registration statement: Registration filing

Aug 13, 2026, 7:00 AM EDT - 4 weeks ago

BioVie Annual report: Q4 2026

Aug 12, 2026, 4:15 PM EDT - 4 weeks ago

BioVie Transcript: Study result

Aug 12, 2026, 4:15 PM EDT - 4 weeks ago

BioVie Slides: Study result

Aug 12, 2026, 4:15 PM EDT - 4 weeks ago

BioVie Press release: Study result

2026-08-06T13:26:51.000Z - 5 weeks ago

BioVie says Phase 2 SUNRISE-PD trial of bezisterim met primary endpoint

Aug 6, 2026, 8:00 AM EDT - 5 weeks ago

BioVie Registration statement: Registration filing

Aug 6, 2026, 7:30 AM EDT - 5 weeks ago

BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease

Jul 31, 2026, 8:00 AM EDT - 6 weeks ago

BioVie Registration statement: Registration filing

2026-07-17T21:25:11.000Z - 1 month ago

BioVie files to sell Class A common stock, warrants, no amount given

Jul 17, 2026, 8:00 AM EDT - 1 month ago

BioVie Registration statement: Registration filing

2026-06-18T21:25:09.000Z - 2 months ago

BioVie files $300M mixed securities shelf

Jun 18, 2026, 8:00 AM EDT - 2 months ago

BioVie Registration statement: Registration filing

Jun 5, 2026, 3:31 PM EDT - 3 months ago

Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Jun 2, 2026, 4:15 PM EDT - 3 months ago

BioVie Transcript: Investor update

Jun 2, 2026, 7:00 AM EDT - 3 months ago

BioVie Slides: Corporate presentation

May 27, 2026, 8:00 AM EDT - 3 months ago

Join BioVie's Exclusive Live Investor Webinar and Q and A Session on June 2

2026-05-26T12:32:11.000Z - 3 months ago

BioVie announces full enrollment of ADDRESS-LC trial of bezisterim

May 26, 2026, 8:00 AM EDT - 3 months ago

BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

2026-05-18T12:08:40.000Z - 3 months ago

BioVie completes SUNRISE-PD trial in early-stage Parkinson’s disease

May 18, 2026, 8:00 AM EDT - 3 months ago

BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson's Disease

May 11, 2026, 7:00 AM EDT - 4 months ago

BioVie Quarterly report: Q3 2026

May 7, 2026, 2:00 PM EDT - 4 months ago

BioVie Transcript: KOL event

Apr 27, 2026, 8:00 AM EDT - 4 months ago

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

Apr 16, 2026, 11:30 AM EDT - 5 months ago

BioVie Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

Apr 14, 2026, 8:00 AM EDT - 5 months ago

BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting

Apr 1, 2026, 7:00 AM EDT - 5 months ago

BioVie Slides: Corporate presentation

Mar 4, 2026, 4:15 PM EST - 6 months ago

BioVie Transcript: Status update

Feb 12, 2026, 12:12 PM EST - 7 months ago

Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights

Feb 6, 2026, 7:00 AM EST - 7 months ago

BioVie Quarterly report: Q2 2026

2026-01-08T13:43:03.000Z - 8 months ago

BioVie completes enrollment in Phase 2 SUNRISE-PD trial

Dec 24, 2025, 2:05 PM EST - 8 months ago

HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Nov 19, 2025, 8:00 AM EST - 9 months ago

Join Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9

Nov 10, 2025, 2:00 PM EST - 10 months ago

BioVie Transcript: AGM 2025

Nov 10, 2025, 7:00 AM EST - 10 months ago

BioVie Quarterly report: Q1 2026

Oct 8, 2025, 4:15 PM EDT - 11 months ago

BioVie Transcript: Investor Update

Sep 26, 2025, 8:00 AM EDT - 11 months ago

BioVie to Host Live Investor Webinar and Q&A on Oct. 8

Sep 25, 2025, 8:00 AM EDT - 11 months ago

BioVie Proxy statement: Proxy Filing

2025-08-29T17:10:18.000Z - 1 year ago

BioVie price target adjusted to $12 from $6 at Brookline

Aug 15, 2025, 7:00 AM EDT - 1 year ago

BioVie Annual report: Q4 2025

Aug 13, 2025, 4:05 PM EDT - 1 year ago

BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

2025-08-09T00:43:00.000Z - 1 year ago

Why Is BioVie Stock (BIVI) Down 50% Today?

2025-08-08T00:50:12.000Z - 1 year ago

BioVie 6M share Secondary priced at $2.00

Aug 7, 2025, 8:43 PM EDT - 1 year ago

BioVie Inc. Announces Pricing of $12 Million Public Offering

Aug 4, 2025, 8:00 AM EDT - 1 year ago

BioVie Registration statement: Registration Filing

2025-07-24T12:20:32.000Z - 1 year ago

BioVie presents data on Bezisterim at WCAG-2025

Jul 24, 2025, 8:00 AM EDT - 1 year ago

BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology

2025-07-22T12:11:30.000Z - 1 year ago

BioVie appoints Amy Chappell, Kameel Farag to board of directors

Jul 22, 2025, 8:00 AM EDT - 1 year ago

BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors

Jul 22, 2025, 8:00 AM EDT - 1 year ago

BioVie Registration statement: Registration Filing

Jul 11, 2025, 8:00 AM EDT - 1 year ago

BioVie Registration statement: Registration Filing

2025-07-09T12:22:03.000Z - 1 year ago

BioVie reports results from bezisterim Phase 3 NM101 study

2025-07-03T20:50:10.000Z - 1 year ago

BioVie Inc. trading halted, news pending

Jul 3, 2025, 8:00 AM EDT - 1 year ago

BioVie Registration statement: Registration Filing

2025-06-26T12:16:13.000Z - 1 year ago

BioVie announces poster on patient-centric accessibility of SUNRISE-PD trial

Jun 26, 2025, 8:00 AM EDT - 1 year ago

BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

Jun 24, 2025, 4:05 PM EDT - 1 year ago

BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress

Jun 23, 2025, 5:00 PM EDT - 1 year ago

BioVie Transcript: AGM 2025

Jun 2, 2025, 8:00 AM EDT - 1 year ago

BioVie Proxy statement: Proxy Filing

May 28, 2025, 12:00 PM EDT - 1 year ago

BioVie Transcript: Status Update

2025-05-15T12:11:23.000Z - 1 year ago

BioVie announces first patient enrollment in Phase 2 ADDRESS-LC trial

2025-05-14T11:57:58.000Z - 1 year ago

BioVie to host KOL event on Phase 2 study of bezisterim

May 14, 2025, 7:30 AM EDT - 1 year ago

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025

May 11, 2025, 6:00 PM EDT - 1 year ago

BioVie Quarterly report: Q3 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

BioVie Proxy statement: Proxy Filing

2025-05-07T12:24:31.000Z - 1 year ago

BioVie to present design of Phase 2 SUNRISE-PD trial

Mar 27, 2025, 8:00 AM EDT - 1 year ago

BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025

Feb 10, 2025, 6:00 PM EST - 1 year ago

BioVie Quarterly report: Q2 2025

Feb 10, 2025, 6:00 PM EST - 1 year ago

BioVie Quarterly report: Q2 2025

Nov 27, 2024, 7:00 AM EST - 1 year ago

BioVie Registration statement: Registration Filing

Nov 21, 2024, 7:00 AM EST - 1 year ago

BioVie Registration statement: Registration Filing

Nov 12, 2024, 6:00 PM EST - 1 year ago

BioVie Quarterly report: Q1 2025

Nov 7, 2024, 1:00 PM EST - 1 year ago

BioVie Transcript: AGM 2024

Oct 28, 2024, 4:10 PM EDT - 1 year ago

UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 28, 2024, 3:13 PM EDT - 1 year ago

BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 24, 2024, 4:10 PM EDT - 1 year ago

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

Oct 23, 2024, 3:24 PM EDT - 1 year ago

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Oct 22, 2024, 8:00 AM EDT - 1 year ago

BioVie Proxy statement: Proxy Filing

Oct 15, 2024, 8:00 AM EDT - 1 year ago

BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin

Oct 11, 2024, 9:00 AM EDT - 1 year ago

BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GENE

Sep 29, 2024, 6:00 PM EDT - 1 year ago

BioVie Annual report: Q4 2024

Sep 27, 2024, 8:00 AM EDT - 1 year ago

BioVie Proxy statement: Proxy Filing

Sep 25, 2024, 4:05 PM EDT - 1 year ago

BioVie Inc. Announces Closing of Public Offering

Sep 23, 2024, 10:26 PM EDT - 1 year ago

BioVie Inc. Announces Pricing of Public Offering

Sep 23, 2024, 4:05 PM EDT - 1 year ago

BioVie Inc. Announces Proposed Public Offering

Sep 17, 2024, 8:00 AM EDT - 1 year ago

BioVie Proxy statement: Proxy Filing

Sep 16, 2024, 8:00 AM EDT - 1 year ago

BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID

Sep 3, 2024, 8:00 AM EDT - 2 years ago

BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID

Aug 27, 2024, 8:45 AM EDT - 2 years ago

BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting

Aug 8, 2024, 6:00 AM EDT - 2 years ago

BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson's Disease

Aug 6, 2024, 4:40 PM EDT - 2 years ago

BioVie Inc. Announces Reverse Stock Split

Jul 5, 2024, 9:00 AM EDT - 2 years ago

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIAF

ValuePrince Sep. 13 at 6:52 AM

$BIVI 🐩

0 · Reply

et1000 Sep. 11 at 11:06 PM

0 · Reply

mshah1615 Sep. 11 at 10:27 AM

$BIVI RedChip Investor Webinar with BioVie (NASDAQ: BIVI) Date & Time Sep 23, 2026 11:00 AM Eastern Time (US and Canada)

0 · Reply

TJ12000 Sep. 9 at 7:18 PM

$BIVI scam company run by greaseball who goes by donkey Kong

1 · Reply

emilyparkerr Sep. 9 at 9:18 AM

0 · Reply

TJ12000 Sep. 8 at 4:06 PM

$BIVI gypsy scam company

0 · Reply

GoldenrodGenius Sep. 8 at 2:30 PM

$BIVI sleeper stock, buy and hold.. still under the radar.

0 · Reply

LibertarianTreehugger Sep. 8 at 2:21 PM

BioVie advances Parkinson’s Phase 3 development program with FDA engagement: https://finance.yahoo.com/healthcare/articles/biovie-advances-parkinson-phase-3-135200836.html $BIVI

0 · Reply

Mistery88 Sep. 8 at 11:51 AM

$BIVI big buy

0 · Reply

mshah1615 Sep. 8 at 12:27 AM

$BIVI I still Believe that IF YOU ARE BULLISH BIVIW IS BEST BUY FOR ROI

1 · Reply

BrassTax Sep. 7 at 1:49 AM

$BIVI still smells like dirty Terren Pizer

0 · Reply

TJ12000 Sep. 4 at 9:23 PM

$BIVI gypsy scam molecule will soon collapse

0 · Reply

BLitt Sep. 4 at 2:07 PM

$BIVI seems I made a mistake

0 · Reply

Rod75b15 Sep. 4 at 1:46 PM

$BIVI

0 · Reply

BLitt Sep. 3 at 1:32 PM

$BIVI im buying more so everyone just wait because it will surely fall. Not advice just being funny. I am getting more though. Good morning all.

0 · Reply

TJ12000 Sep. 2 at 4:24 PM

$BIVI buy the dip, buy the dip ! Gypsies gotta eat too 🤣

0 · Reply

Rod75b15 Sep. 2 at 3:40 PM

$BIVI It's just a matter of patience, the markets are too red these days.

0 · Reply

TJ12000 Sep. 2 at 3:04 PM

$BIVI incognito mode activated…do-na Kong while gypsy scam collapses

0 · Reply

sahcrete Sep. 2 at 2:27 PM

$BIVI i might be out ngl

2 · Reply

BLitt Sep. 2 at 2:13 PM

$BIVI

0 · Reply

TJ12000 Sep. 2 at 1:50 PM

$BIVI gypsy scam with kongs miracle molecule 🤣😂🤣

1 · Reply

sahcrete Sep. 2 at 1:35 PM

$BIVI what’s going on

0 · Reply

Market Cap	16.31M
Revenue (ttm)	0.00
Net Income (ttm)	-22.07M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	170,700
Avg Vol	5,779,312
Day's Range	N/A - N/A
Shares Out	8.45M
Stochastic %K	7%
Beta	0.74
Analysts	Strong Buy
Price Target	$12.00